Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Open-label, Phase 1 Study Investigating the Safety and Tolerability of Encorafenib Monotherapy in BRAF V600E-mutated Chinese Patients With Advanced Metastatic Solid Tumors

NCT05003622 is registered in ClinicalTrials.gov with Pierre Fabre Medicament as lead sponsor.

NCT NCT05003622
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05003622 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Open-label, Phase 1 Study Investigating the Safety and Tolerability of Encorafenib Monotherapy in BRAF V600E-mutated Chinese Patients With Advanced Metastatic Solid Tumors
Lead sponsor
Pierre Fabre Medicament
Phase
Phase 1
Overall status
Completed
Start date
September 27, 2021
Completion date
May 6, 2022
Enrollment
3 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

braf v600e metastatic nsclc, braf v600e unresectable or metastatic melanoma, melanoma